


## CLAIMS LISTING

1. (Withdrawn from consideration) Compounds of formula I:



wherein

$R^1 = \text{H}$ , or  $\text{C}_1\text{-C}_{20}$  alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl,  $=\text{CHR}^3$ ,  $-\text{C}(\text{O})\text{OR}^3$ ,

$-\text{C}(\text{O})\text{R}^3$ ,  $-\text{CH}_2\text{C}(\text{O})\text{OR}^3$ ,  $-\text{CH}_2\text{C}(\text{O})\text{NHR}^3$ , where  $\text{R}^3$  is  $\text{H}$  or  $\text{C}_1\text{-C}_{10}$  alkyl, cycloalkyl, or alkenyl;


$\text{R}^2 = \text{C}_1\text{-C}_{20}$  alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl;

$\text{X}^1 = \text{NHR}^4$ , where  $\text{R}^4$  is  $\text{H}$ ,  $\text{C}_1\text{-C}_{20}$  alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, the  $\text{R}^4$  group optionally containing a carbonyl group, a carboxyl group, a carboxyamide group, an alcohol group, or an ether group, the  $\text{R}^4$  group further optionally containing one or more halogen atoms.

2. (Withdrawn) The compounds of claim 1, wherein  $\text{R}^1$  is  $\text{H}$ , or  $\text{C}_1\text{-C}_{10}$  alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, or  $=\text{CH}_2$ .


3. (Withdrawn) The compounds of claim 2, wherein  $\text{R}^1$  is  $-\text{CH}_3$  or  $=\text{CH}_2$ .

4. (Withdrawn) The compounds of claim 3, wherein the compound is selected from the group consisting of:




5. (Withdrawn) The compounds of claim 1 wherein  $R^4$  is  $-\text{CH}_2\text{C}(\text{O})\text{OR}^5$  or  $-\text{CH}_2\text{C}(\text{O})\text{NHR}^5$ , where  $R^5$  is H,  $\text{C}_1\text{-C}_{10}$  alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl.

6. (Withdrawn) The compounds of claim 1, wherein the compound is selected from the group consisting of:



7. (Withdrawn) Compounds of formula II:



wherein

$R^6 = \text{H}$ , or  $\text{C}_1\text{-C}_{20}$  alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl,  $-\text{C}(\text{O})\text{OR}^8$ ,  $-\text{C}(\text{O})\text{R}^8$ ,  $-\text{CH}_2\text{C}(\text{O})\text{OR}^8$ ,  $-\text{CH}_2\text{C}(\text{O})\text{NHR}^8$ , where  $\text{R}^8$  is  $\text{H}$  or  $\text{C}_1\text{-C}_{10}$  alkyl, cycloalkyl, or alkenyl;

$\text{R}^7 = \text{C}_1\text{-C}_{20}$  alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl and

$\text{X}^2 = \text{NHR}^9$ , where  $\text{R}^9$  is  $\text{H}$ ,  $\text{C}_1\text{-C}_{20}$  alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, the  $\text{R}^9$  group optionally containing a carbonyl group, a carboxyl group, a carboxyamide group, an alcohol group, or an ether group, the  $\text{R}^9$  group further optionally containing one or more halogen atoms;


with the proviso that when  $\text{R}^6$  is  $-\text{CH}_3$ , and  $\text{R}^7$  is  $n\text{-C}_{13}\text{H}_{27}$ ,  $\text{X}^2$  is not  $-\text{NHC}_2\text{H}_5$ .

8. (Withdrawn) The compounds of claim 7, wherein  $\text{R}^6$  is  $\text{C}_1\text{-C}_{20}$  alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl

9. (Withdrawn) The compounds of claim 8, wherein  $\text{R}^6$  is  $-\text{CH}_3$ .

10. (Withdrawn) The compounds of claim 7, wherein  $\text{R}^9$  is  $-\text{CH}_2\text{C}(\text{O})\text{OR}^{10}$  or  $-\text{CH}_2\text{C}(\text{O})\text{NHR}^{10}$ , where  $\text{R}_{10}$  is  $\text{H}$ ,  $\text{C}_1\text{-C}_{20}$  alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl

11. (Withdrawn) Compounds of formula IV:



wherein

$R^{16}$  = H, or  $C_1$ - $C_{20}$  alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl,  $-C(O)OR^{18}$ ,  $-C(O)R^{18}$ ,  $-CH_2C(O)OR^{18}$ ,  $-CH_2C(O)NHR^{18}$ , where  $R^{18}$  is H or  $C_1$ - $C_{10}$  alkyl, cycloalkyl, or alkenyl;

$R^{17}$  =  $C_1$ - $C_{20}$  alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl;

$X^4$  =  $OR^{19}$ , where  $R^{19}$  is  $C_1$ - $C_{20}$  alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, the  $R^{19}$  group optionally containing a carbonyl group, a carboxyl group, a carboxamide group, an alcohol group, or an ether group, the  $R^{19}$  group further optionally containing one or more halogen atoms;

with the proviso that when  $R^{16}$  is  $-CH_3$  and  $R^{19}$  is  $-CH_3$ , then  $R^{17}$  is not substituted or unsubstituted phenyl,  $-nC_3H_7$ ,  $-nC_5H_{11}$ ,  $-nC_{13}H_{27}$


and with the further proviso that when  $R^{16}$  is H and  $R^{19}$  is  $-CH_3$ , then  $R^{17}$  is not substituted or unsubstituted phenyl or  $-CH_3$ , and when  $R^{16}$  is H and  $R^{19}$  is  $-CH_2CH_3$ , then  $R^{17}$  is not  $-iC_3H_7$ , or substituted or unsubstituted phenyl.

12. (Withdrawn) The compounds of claim 11, wherein  $R^{16}$  is  $C_1$ - $C_{10}$  alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl.

13. (Withdrawn) The compounds of claim 12, wherein  $R^{16}$  is  $-CH_3$ .

14. (Withdrawn) The compounds of claim 11, wherein  $R^{19}$  is  $-CH_2C(O)OR^{20}$  or  $-CH_2C(O)NHR^{20}$ , where  $R^{20}$  is  $C_1$ - $C_{10}$  alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl.

15. (Currently amended) Compounds of formula V:



wherein

$R^{21} = C_2-C_{20}$  alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl,  $=CHR^{23}$ ,  $-C(O)OR^{23}$ ,

$-C(O)R^{23}$ ,  $-CH_2C(O)OR^{23}$ ,  $-CH_2C(O)NHR^{23}$ , where  $R^{23}$  is H or  $C_1-C_{10}$  alkyl, cycloalkyl,

or alkenyl, except when  $R^{21}$  is  $=CHR^{23}$ ,  $R^{23}$  is not H;

$R^{22} = C_2-C_{20}$  alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl


with the proviso that when  $R^{21}$  is  $-COOH$ , then  $R^{22}$  is not  $-CH_3$ ,  $-nC_5H_{11}$ , or  $C_{13}H_{27}$ , and with the

further proviso that when  $R^{21}$  is  $-CH_2COOH$ , then  $R^{22}$  is not  $-CH_3$ ,  $-CH_2CH_3$ , or  $-iC_5H_{11}$ .

16. (Currently amended) The compounds of claim 15, wherein  $R^{21}$  is  $C_2-C_{10}$  alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl.

17. (Cancelled).

18. (Withdrawn) Compounds of formula VI:



VI

wherein:


$R^{24} = C_2-C_{20}$  alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl,  $-C(O)OR^{26}$ ,  $-C(O)R^{26}$ ,  $-CH_2C(O)OR^{26}$ ,  $-CH_2C(O)NHR^{26}$ , where  $R^{26}$  is H or  $C_1-C_{10}$  alkyl, cycloalkyl, or alkenyl;

$R^{25} = C_1-C_{20}$  alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl;

with the proviso that when  $R^{24}$  is  $-COOH$ , then  $R^{25}$  is not  $-CH_3$ ,  $-nC_5H_{11}$ , or  $C_{13}H_{27}$ , and with the further proviso that when  $R^{24}$  is  $-CH_2COOH$ , then  $R^{25}$  is not  $-CH_3$ ,  $-CH_2CH_3$ , or  $-iC_5H_{11}$ .

19. (Withdrawn) The compounds of claim 18, wherein  $R^{21}$  is  $C_2-C_{10}$  alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl.

20. (Previously presented) Compounds of formula VII:




VII

wherein  $R^{27} = C_{12}$  alkyl,  $C_{14}$  alkyl, or  $C_{16}-C_{20}$  alkyl.

21-22. (Cancelled)

23. (Withdrawn) A pharmaceutical composition comprising a pharmaceutical diluent and a compound of formula IX:



$R^{29}$  = H, or  $C_1$ - $C_{20}$  alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl,  $=CHR^{31}$ ,  $-C(O)OR^{31}$ ,  $-C(O)R^{31}$ ,  $-CH_2C(O)OR^{31}$ ,  $-CH_2C(O)NHR^{31}$ , where  $R^{31}$  is H or  $C_1$ - $C_{10}$  alkyl, cycloalkyl, or alkenyl;

$R^{30}$  =  $C_1$ - $C_{20}$  alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl;

$X^5$  =  $-OR^{32}$ , or  $-NHR^{32}$ , where  $R^{32}$  is H,  $C_1$ - $C_{20}$  alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, the  $R^{32}$  group optionally containing a carbonyl group, a carboxyl group, a carboxyamide group, an alcohol group, or an ether group, the  $R^{32}$  group further optionally containing one or more halogen atoms;

with the proviso that when  $R^{29}$  is  $=CH_2$ , then  $X^5$  is not OH.

24. (Withdrawn) The pharmaceutical compositions of claim 23, wherein  $R^{29}$  is  $C_1$ - $C_{10}$  alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, or  $=CH_2$ .


25. (Withdrawn) The pharmaceutical compositions of claim 24, wherein  $R^{29}$  is  $-CH_3$  or  $=CH_2$ .



26. (Withdrawn) The pharmaceutical compositions of claim 23, wherein R<sup>32</sup> is -CH<sub>2</sub>C(O)OR<sup>33</sup> or -CH<sub>2</sub>C(O)NHR<sup>33</sup>, where R<sup>33</sup> is C<sub>1</sub>-C<sub>10</sub> alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl.

27. (Withdrawn) The pharmaceutical compositions of claim 23, where R<sup>29</sup> is -C<sub>6</sub>H<sub>13</sub> or -C<sub>8</sub>H<sub>17</sub>.

28. (Withdrawn) The pharmaceutical compositions of claim 23, wherein the compound is selected from the group consisting of:



29. (Withdrawn) A pharmaceutical composition comprising a pharmaceutical diluent and a compound according to claim 1.

30. (Withdrawn) A pharmaceutical composition comprising a pharmaceutical diluent and a compound according to claim 7.

31. (Withdrawn) A pharmaceutical composition comprising a pharmaceutical diluent and a compound according to claim 11.


32. (Original) A pharmaceutical composition comprising a pharmaceutical diluent and a compound according to claim 15.

33. (Withdrawn) A pharmaceutical composition comprising a pharmaceutical diluent and a compound according to claim 18.

34. (Original) A pharmaceutical composition comprising a pharmaceutical diluent and a compound according to claim 20.

35. A pharmaceutical composition comprising a pharmaceutical diluent and a compound according to claim 22.

36. (Withdrawn) A pharmaceutical composition comprising a pharmaceutical diluent and a compound according to Formula III:.



III

wherein

$R^{11}$  = H, or  $C_1$ - $C_{20}$  alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl,  $=CHR^{13}$ ,  $-C(O)OR^{13}$ ,  $-C(O)R^{13}$ ,  $-CH_2C(O)OR^{13}$ ,  $-CH_2C(O)NHR^{13}$ , where  $R^{13}$  is H or  $C_1$ - $C_{10}$  alkyl, cycloalkyl, or alkenyl;

$R^{12}$  =  $C_1$ - $C_{20}$  alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl;

$X^3$  =  $OR^{14}$ , where  $R^{14}$  is  $C_1$ - $C_{20}$  alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, the  $R^{14}$  group optionally containing a carbonyl group, a carboxyl group, a carboxamide group, an alcohol group, or an ether group, the  $R^{14}$  group further optionally containing one or more halogen atoms.

37. (Withdrawn) The pharmaceutical formulation of claim 36, wherein  $R^{11}$  is  $C_1$ - $C_{10}$  alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, or  $=CH_2$ .

38. (Withdrawn) The pharmaceutical formulation of claim 37, wherein  $R^{11}$  is  $-CH_3$  or  $=CH_2$ .


39. (Withdrawn) The pharmaceutical formulation of claim 36, wherein  $R^{14}$  is  $-CH_2C(O)OR^{15}$  or  $-CH_2C(O)NHR^{15}$ , where  $R^{15}$  is  $C_1$ - $C_{10}$  alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl.

40. (Withdrawn) A method of inducing weight loss in an animal or human subject comprising administering an effective amount of a pharmaceutical composition according to claim 23 to said subject.


41. (Withdrawn) The method of claim 40, wherein the subject is a human.

42. (Withdrawn) The method of claim 40, wherein the subject is an animal.

43. (Withdrawn) The method of claim 41, wherein the pharmaceutical composition comprises a compound selected from the group consisting of:



44. (Withdrawn) The method of claim 42, wherein the pharmaceutical composition comprises a compound selected from the group consisting of:








45. (Withdrawn) A method of inhibiting growth of cancer cells in an animal or human subject, comprising administering an effective amount of a pharmaceutical composition according to claim 23 to said subject.






46. (Withdrawn) The method of claim 45, wherein the subject is a human.

47. (Withdrawn) The method of claim 45, wherein the subject is an animal.

48. (Withdrawn) The method of claim 46, wherein the pharmaceutical composition comprises a compound selected from the group consisting of:

(±)	(±)	(±)	(±)
			
(±)			
			

49. (Withdrawn) The method of claim 47, wherein the pharmaceutical composition comprises a compound selected from the group consisting of:


(±)	(±)	(±)	(±)
			
(±)			
			

50. (Withdrawn) A method of stimulating the activity of CPT-1 in an animal or human subject comprising administering an effective amount of a pharmaceutical composition according to claim 23 to said subject.


51. (Withdrawn) The method of claim 50, wherein the subject is a human.

52. (Withdrawn) The method of claim 50, wherein the subject is an animal.

53. (Withdrawn) The method of claim 51, wherein the compound is:



54. (Withdrawn) The method of claim 52, wherein the compound is:



55. (Withdrawn) A method of inhibiting the activity of neuropeptide-Y in an animal or human subject comprising administering an effective amount of a pharmaceutical composition according to claim 23 to said subject.

56. (Withdrawn) The method of claim 55, wherein the subject is a human.

57. (Withdrawn) The method of claim 55, wherein the subject is an animal.

58. (Withdrawn) A method of inhibiting fatty acid synthase activity in an animal or human subject comprising administering an effective amount of a pharmaceutical composition according to claim 23 to said subject.


59. (Withdrawn) The method of claim 58, wherein the subject is a human.

60. (Withdrawn) The method of claim 58, wherein the subject is an animal.

61. (Withdrawn) The method of claim 59, wherein the compound is selected from the group consisting of:

		(4)	
(1)	(2)	(3)	(4)
	(1)		


62. The method of claim 60, wherein the compound is selected from the group consisting of:




63. (Withdrawn) A method of inhibiting growth of invasive microbial cells in an animal or human subject comprising the administration of an effective amount of a pharmaceutical composition according to claim 23 to said subject.

64.-65 (Cancelled)

66. (Withdrawn) The method of claim 64, wherein the compound is selected from the group consisting of:



67. (Withdrawn) The method of claim 65, wherein the compound is selected from the group consisting of:





69. (New) Compounds according to claim 15, wherein

$R^{21}$  = cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl,  $=CHR^{23}$ ,  $-C(O)OR^{23}$ ,  $-C(O)R^{23}$ , -

$CH_2C(O)OR^{23}$ ,  $-CH_2C(O)NHR^{23}$ , where  $R^{23}$  is H or  $C_1$ - $C_{10}$  alkyl, cycloalkyl, or alkenyl,

except when  $R^{21}$  is  $=CHR^{23}$ ,  $R^{23}$  is not H;


$R^{22}$  =  $C_2$ - $C_{20}$  alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl

with the proviso that when  $R^{21}$  is  $-COOH$ , then  $R^{22}$  is not  $-C_{13}H_{27}$ , and with the further proviso

that when  $R^{21}$  is  $-CH_2COOH$ , then  $R^{22}$  is not,  $-CH_2CH_3$ , or  $-iC_5H_{11}$ .

70. (New) A pharmaceutical composition comprising a pharmaceutical diluent and a compound according to claim 69.

71. (New) Compounds of formula X:



wherein

$R^{42}$  =  $C_2$ - $C_{20}$  alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl

72. (New) A pharmaceutical composition comprising a pharmaceutical diluent and a compound according to claim 71.